Professional Medicated Dna Collection
Loading...Professional Medicated Dna Collection Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
EXCESSIVE DOSAGE, OR SHORT INTERVALS BETWEEN DOSES, CAN RESULT IN HIGH PLASMA LEVELS AND SERIOUS ADVERSE EFFECTS. PATIENTS SHOULD BE INSTRUCTED TO STRICTLY ADHERE TO THE RECOMMENDED DOSAGE AND ADMINISTRATION GUIDELINES AS SET FORTH IN THIS PACKAGE INSERT.
THE MANAGEMENT OF SERIOUS ADVERSE REACTIONS MAY REQUIRE THE USE OF RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS.
Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% should be used with extreme caution if the mucosa in the area of application has been traumatized, since under such conditions there is the potential for rapid systemic absorption.
If pain, irritation, redness, or swelling occurs, discontinue use and consult a physician.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
For post operative oral care, relief of dry mouth, and swabbing when special mouth care is prescribed. If swallowed, get medical help or contact poison control center right away
History
There is currently no drug history available for this drug.
Other Information
Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains a local anesthetic agent and is administered topically. Lidocaine Hydrochloride Oral Topical Solution, USP (Viscous) 2% contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-N- (2,6-dimethylphenyl)- , monohydrochloride and has the following structural formula:
The molecular formula of lidocaine is C14H22N2O. The molecular weight is 234.34.
Each mL contains 20 mg of lidocaine HCl. In addition each mL contains the following inactive ingredients: Carboxymethylcellulose sodium, methylparaben, natural orange flavor, propylparaben, purified water, saccharin sodium. The pH is adjusted to 5.0 to 7.0 by means of hydrochloric acid and/or sodium hydroxide.
Purified Water USP, Citric acid USP, Sodium Benzoate 0.1% as a preservative. Remove one stick at a time.
Sources
Professional Medicated Dna Collection Manufacturers
-
Sircle Laboratories, Llc
![Professional Medicated Dna Collection (Lidocaine Hydrochloride And Glycerin) Kit [Sircle Laboratories, Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Professional Medicated Dna Collection | Novartis Animal Health Us, Inc.
INTERCEPTOR PLUS should be administered orally, once every month, at the minimum dosage of 0.23 mg/lb (0.5 mg/kg) milbemycin oxime, and 2.28 mg/lb (5 mg/kg) praziquantel. For heartworm prevention, give once monthly for at least 6 months after exposure to mosquitoes (see EFFECTIVENESS).
Dosage Schedule Body
Weight Milbemycin
Oxime per
chewable Praziquantel
per
chewable Number of
chewables 2 to 8 lbs. 2.3 mg 22.8 mg One 8.1 to 25 lbs. 5.75 mg 57 mg One 25.1 to 50 lbs. 11.5 mg 114 mg One 50.1 to 100 lbs. 23 mg 228 mg One Over 100 lbs. Administer the appropriate combination of chewables.INTERCEPTOR PLUS may be offered to the dog by hand or added to a small amount of dog food. The chewables should be administered in a manner that encourages the dog to chew, rather than to swallow without chewing. Chewables may be broken into pieces and fed to dogs that normally swallow treats whole. Care should be taken that the dog consumes the complete dose, and treated animals should be observed for a few minutes after administration to ensure that no part of the dose is lost or rejected. If it is suspected that any of the dose has been lost, redosing is recommended.
Heartworm Prevention:INTERCEPTOR PLUS should be administered at monthly intervals beginning within 1 month of the dog's first seasonal exposure to mosquitoes and continuing until at least 6 months after the dog's last seasonal exposure (see EFFECTIVENESS). INTERCEPTOR PLUS may be administered year-round without interruption. When switching from another heartworm preventative product to INTERCEPTOR PLUS, the first dose of INTERCEPTOR PLUS should be given within a month of the last dose of the former product.
Intestinal Nematode and Cestode Treatment and Control:Dogs may be exposed to and can become infected with roundworms, whipworms, hookworms, and tapeworms throughout the year, regardless of season or climate. Clients should be advised of appropriate measures to prevent reinfection of their dog with intestinal parasites. Because the prepatent period for E. multilocularis may be as short as 26 days, dogs treated at the labeled monthly intervals may become reinfected and shed eggs between treatments.
Login To Your Free Account